stockrow
Saturday 7 November 2026
Export SER’s income statement to Excel — free account
Serina Therapeutics, Inc.
Serina Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $130,000.00, up 132.1% from fiscal 2024.
- Revenue
- +2,500.0%
- EPS
- +16.7%
- Free cash flow
- −76.8%
Quarter to June 2026, against a year earlier
1.40
0.25
−15.15%
Follow SER
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.25 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | 2 | 3 | 2 | 1 | 1 | 6 | 1 | 2 |
P/S ratio |
0.00 | 0.00 | 76.66 | 39.22 | 158.43 | 286.49 | 623.92 | 10.44 | 658.37 | 107.53 |
Altman Z-Score |
— | — | 13.19 | (13.01) | (40.28) | (56.11) | (59.50) | (4.71) | (13.44) | (22.07) |
Altman Z″-Score (non-manufacturers) |
(165.44) | (16.24) | (22.84) | (47.87) | (103.66) | (141.04) | (147.67) | (10.69) | (35.21) | (50.64) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | (3.53) | (2.24) | (3.06) | (5.33) | (5.39) | (10.44) | 82.88 | — | — |
P/Operating CF |
(54.34) | (54.34) | (52.31) | (28.11) | (35.30) | (25.05) | (16.06) | 272.08 | (8.03) | (3.23) |
P/B ratio |
11.65 | 11.65 | 13.00 | 25.89 | 0.00 | 0.00 | 0.00 | 0.00 | 72.58 | 0.00 |
Price to Tangible BV |
11.65 | 11.65 | 19.38 | 145.42 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 71.86 | 38.99 | 174.41 | 374.11 | 1,138.00 | 9.46 | 673.33 | 122.88 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.00 | (7.32) | (12.55) | (6.63) | (8.05) | (6.86) | (6.51) | (12.04) | (2.20) | (1.24) |
EV/FCF |
0.00 | (7.30) | (12.51) | (6.24) | (8.03) | (6.84) | (6.49) | (10.00) | (2.20) | (1.23) |
Quick Ratio |
0.02 | 5.70 | 2.80 | 0.82 | 0.16 | 0.07 | 0.06 | 5.39 | 1.55 | 0.86 |
Current Ratio |
0.03 | 5.79 | 3.22 | 1.23 | 0.43 | 0.25 | 0.24 | 5.39 | 2.40 | 1.71 |
Net Debt/EBITDA |
0.02 | 1.24 | 0.63 | 0.07 | (0.40) | (0.82) | (2.65) | 1.53 | 0.22 | 0.00 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 20.53% | 99.36% | 192.20% | 323.30% | 33.27% | 0.00% | 42.38% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.58 | (0.72) | (0.51) | (0.61) | (0.09) | 0.00 | (79.62) |
Asset Turnover |
0.26 | 0.22 | 0.14 | 0.19 | 0.06 | 0.04 | 0.01 | 0.52 | 0.01 | 0.02 |
Operating CF/Net income |
0.54 | 0.96 | 1.07 | 0.84 | 0.72 | 0.91 | 0.57 | (0.47) | 1.54 | 0.94 |
Capex/Depreciation |
0.00 | 0.00 | (0.04) | (0.64) | (0.01) | 0.00 | 0.00 | (5.60) | (0.04) | (0.45) |
Interest Coverage |
(1,019.12) | — | (96.94) | (433.07) | (25.00) | (7.23) | (2.09) | (5.61) | (32.41) | (112.78) |
| 191.98% | 87.15% | (90.66%) | (224.08%) | 781.94% | 100.46% | 71.68% | (21.24%) | 70.10% | 858.45% | |
| (241.05%) | (102.38%) | (73.90%) | (134.20%) | (191.17%) | (245.09%) | (327.19%) | 86.31% | (142.00%) | (280.54%) | |
ROIC |
0.00% | (441.14%) | (461.16%) | (437.78%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
62.68% | (102.65%) | (136.33%) | (645.46%) | 353.45% | 128.84% | 137.21% | 77.73% | (292.34%) | (643.26%) |
Average Days of Receivables |
67.48 | 27.82 | 34.25 | 76.68 | 329.61 | 63.37 | 42.94 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
472.51% | 411.97% | 417.62% | 341.67% | 1,028.81% | 1,011.11% | 3,014.71% | 75.74% | 13,357.14% | 10,119.23% |
Selling, General and Administrative Expense of Revenue |
337.45% | 275.57% | 404.51% | 471.01% | 1,861.77% | 4,658.33% | 17,561.76% | 123.50% | 17,185.71% | 8,459.23% |
Intangible Assets out of Total Assets |
0.71 | 0.19 | 0.25 | 0.29 | 0.41 | 0.28 | 0.23 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 53.56% | 105.52% | 110.36% | 251.80% | 693.75% | 2,235.29% | 0.79% | 4,633.93% | 2,917.69% |
Graham Net Nets |
0.08 | 0.08 | 0.05 | (0.01) | (0.12) | (0.31) | (0.85) | (1.02) | (0.01) | (0.05) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 34.04 | 45.51 | 58.59 | 0.00 | 0.00 | 4.58 |
Earnings Yield |
(11.81%) | (22.51%) | (7.28%) | (18.70%) | (19.10%) | (21.76%) | (48.36%) | 16.00% | (97.94%) | (100.00%) |
Free Cash Flow Yield |
0.00% | (12.65%) | (7.49%) | (15.94%) | (13.70%) | (19.09%) | (28.09%) | (9.05%) | (46.54%) | (92.58%) |
Revenue per Share |
0.05 | 1.61 | 1.41 | 1.63 | 0.34 | 0.13 | 0.03 | 1.41 | 0.01 | 0.01 |
Operating CF per Share |
(0.24) | (7.22) | (8.06) | (9.60) | (7.31) | (7.30) | (5.50) | (1.11) | (2.33) | (1.76) |
Capex per Share |
0.00 | 0.00 | (0.02) | (0.61) | (0.02) | 0.00 | 0.00 | (0.23) | 0.00 | (0.01) |
Free Cash Flow per Share |
(0.24) | (7.22) | (8.08) | (10.20) | (7.33) | (7.30) | (5.50) | (1.33) | (2.33) | (1.77) |
Cash per Share |
0.01 | 8.47 | 6.76 | 2.22 | 0.49 | 0.54 | 0.60 | 3.41 | 0.50 | 0.30 |
Shareholders Equity per Share |
(0.65) | 9.56 | 8.30 | 2.47 | (5.04) | (11.04) | (16.05) | (14.45) | 0.07 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.65) | 9.56 | 8.30 | 2.47 | (5.04) | (11.04) | (16.05) | (14.45) | 0.07 | 0.00 |
Free Cash Flow |
(8.43) | (6.29) | (8.02) | (10.80) | (7.84) | (7.85) | (5.94) | (2.98) | (17.16) | (18.01) |
Working Capital |
(24.91) | 6.28 | 5.41 | 0.76 | (3.07) | (6.73) | (7.62) | 6.21 | 3.31 | 2.52 |
Capital Expenditures |
(0.02) | 0.00 | (0.02) | (0.64) | (0.02) | — | — | (0.50) | (0.02) | (0.06) |
Net Current Asset Value |
(24.91) | 6.28 | 5.41 | (0.77) | (7.04) | (12.79) | (18.10) | (33.64) | (0.54) | (0.91) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.02 | 0.37 | 0.06 | 0.00 | 0.00 | 0.16 | 0.39 | 0.45 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
4.33 | 5.42 | 5.94 | 0.89 | 0.00 | 0.00 | 0.00 | 0.16 | 1.08 | 0.28 |
Cash ROIC |
36.39% | (40.05%) | (53.66%) | (166.25%) | 808.77% | 150.22% | 95.91% | 13.74% | (410.50%) | (301.99%) |
Accounts Receivable Turnover |
8.03 | 6.77 | 11.73 | 7.00 | 1.05 | 0.82 | 2.34 | 103.38 | 0.00 | 0.00 |
Accounts Payable Turnover |
5.42 | 0.33 | 0.34 | 0.17 | 0.02 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
104.57 | 1,668.57 | 1,369.75 | 2,366.52 | 23,247.69 | 14,811.32 | 29,031.54 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Receivables |
0.21 | 0.21 | 0.12 | 0.25 | 0.34 | 0.18 | 0.01 | 0.03 | — | — |
Average Payables |
0.17 | 0.51 | 1.07 | 1.47 | 1.62 | 1.21 | 0.90 | 0.81 | 0.66 | 1.34 |
Average Assets |
6.43 | 6.43 | 10.15 | 9.06 | 5.68 | 3.54 | 3.20 | 6.10 | 7.85 | 6.84 |
Average Common Equity |
(8.07) | (7.55) | 8.28 | 5.42 | (1.39) | (8.64) | (14.59) | (24.80) | (15.89) | (2.23) |
Columns are period end dates · fundamentals updated 25 Oct 2026